The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mitiglinide     calcium(2S)-4-[(3aS,7aR)- 1,3,3a,4,5,6,7...

Synonyms: AC1NUHLY, SureCN1649332, KAD1229, CS-1126, HY-17398, ...
This record was replaced with 121891.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid

  • Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent [1].
  • The effects exerted by KAD-1229 on the post-prandial plasma glucose rise in STZ-induced mild NIDDM (mNIDDM) rats were different from those of sulfonylureas [2].
  • We also tested the efficacy of KAD-1229 in more severe STZ-induced NIDDM (sNIDDM) rats to elucidate the effects of the drug on the long-term glycemic controls and diabetic complications [2].
  • In this model, KAD-1229 reduced the increase in plasma glucose level without producing hypoglycemia [3].
  • The results suggest that in type 2 diabetes caused by, at least, insulin deficiency, KAD-1229 may improve impaired insulin secretion in the early phase and attenuate hyperglycemia without causing a sustained hypoglycemia [3].

High impact information on (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid


Chemical compound and disease context of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid


Biological context of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid


Anatomical context of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid

  • In a receptor-binding experiment, unlabeled glibenclamide completely inhibited [(3)H]glibenclamide binding to the myocardium, but KAD-1229 did not [1].
  • 3. It is speculated that the ionophoretic property of KAD-1229 might participate to the remodelling of cationic fluxes evoked by this insulinotropic agent in pancreatic islet cells [9].

Associations of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid with other chemical compounds


Gene context of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid

  • 7. We conclude that KAD-1229 stimulates insulin and somatostatin release, while it inhibits glucagon release following transient stimulation [4].
  • We have investigated the hypoglycemic effects of the newly synthesized short-acting nonsulphonylurea hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)-propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus (NIDDM) rats [13].
  • The two shortest-acting compounds, A-4166 and KAD-1229, will be developed to be taken prior to each main meal, while the slower, longer duration agents, repaglinide and BTS 67 582, may be developed to be taken twice daily [12].

Analytical, diagnostic and therapeutic context of (2S)-4-[(3aS,7aR)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxo-butanoic acid


  1. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, a novel hypoglycemic agent. Ichikawa, K., Maruyama, K., Murakami, M., Tsuji, A., Yamato, T., Kusama, H., Kojima, M. Eur. J. Pharmacol. (2001) [Pubmed]
  2. A rapid- and short-acting hypoglycemic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in streptozotocin-induced non-insulin-dependent diabetes mellitus rats. Ohnota, H., Kitamura, T., Kinukawa, M., Hamano, S., Shibata, N., Miyata, H., Ujiie, A. Jpn. J. Pharmacol. (1996) [Pubmed]
  3. Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Misawa, K., Ichikawa, K., Ojima, K., Hamano, S., Kitamura, T., Komatsu, H. Pharmacology (2001) [Pubmed]
  4. Effect of a non-sulphonylurea hypoglycaemic agent, KAD-1229 on hormone secretion in the isolated perfused pancreas of the rat. Kinukawa, M., Ohnota, H., Ajisawa, Y. Br. J. Pharmacol. (1996) [Pubmed]
  5. In vitro insulinotropic action of a new non-sulfonylurea hypoglycemic agent, calcium (2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl-carbonyl) propionate dihydrate (KAD-1229), in rat pancreatic B-cells. Ohnota, H., Kobayashi, M., Koizumi, T., Katsuno, K., Sato, F., Aizawa, T. Biochem. Pharmacol. (1995) [Pubmed]
  6. Novel rapid- and short-acting hypoglycemic agent, a calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. Ohnota, H., Koizumi, T., Tsutsumi, N., Kobayashi, M., Inoue, S., Sato, F. J. Pharmacol. Exp. Ther. (1994) [Pubmed]
  7. Inhibition of ATP-sensitive K+ channel by a non-sulfonylurea compound KAD-1229 in a pancreatic beta-cell line, MIN 6 cell. Mogami, H., Shibata, H., Nobusawa, R., Ohnota, H., Satou, F., Miyazaki, J., Kojima, I. Eur. J. Pharmacol. (1994) [Pubmed]
  8. Effect of a novel hypoglycemic agent, KAD-1229 on glucose metabolism and fructose-2,6-bisphosphate content in isolated hepatocytes of normal rats. Nakashima, E., Nakamura, J., Koh, N., Sakakibara, F., Hamada, Y., Hotta, N. Diabetes Res. Clin. Pract. (1996) [Pubmed]
  9. Insulinotropic action of (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl) propionate. II. Ionophoretic and conformational aspects. Malaisse, W.J., Nadi, A.B., Malaisse-Lagae, F., Sato, F., Lins, L., Brasseur, R. Gen. Pharmacol. (1995) [Pubmed]
  10. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Sunaga, Y., Gonoi, T., Shibasaki, T., Ichikawa, K., Kusama, H., Yano, H., Seino, S. Eur. J. Pharmacol. (2001) [Pubmed]
  11. Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations. Malaisse, W.J. Pharmacol. Res. (1995) [Pubmed]
  12. New non-sulfonylurea insulin secretagogues. Dunning, B.E. Expert opinion on investigational drugs. (1997) [Pubmed]
  13. Normalization of impaired glucose tolerance by the short-acting hypoglycemic agent calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate (KAD-1229) in non-insulin-dependent diabetes mellitus rats. Ohnota, H., Koizumi, T., Kobayashi, M., Momose, Y., Sato, F. Can. J. Physiol. Pharmacol. (1995) [Pubmed]
WikiGenes - Universities